HCV Self-testing in Georgia

NCT ID: NCT04961723

Last Updated: 2022-02-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 1250 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-10
• Study Completion Date: 2022-08-31

Brief Summary

Self-testing with easy-to-use rapid diagnostic tests has been successfully used for diseases such as HIV. The availability of self-testing has been shown to increase testing rates and testing acceptability in diverse populations around the world, in large part due to its convenience and privacy advantages.7 Self-testing has also been effectively used to reach key populations who may not be covered by traditional healthcare programs, such as persons who inject drugs (PWID) and men who have sex with men (MSM). In Georgia, HIV self-testing has been offered to MSM through an online platform promoting their uptake.11-12 In the present study aims to evaluate the acceptability and impact of using an online platform to enable home delivery of HCV self-testing in Georgia for PWID and MSM.

Detailed Description

Georgia, a middle-income country with an estimated population of 3.7 million people, is among the world's highest-burden countries for HCV, with an estimated sero-prevalence of 7.7% in the general population and a higher burden of disease in high-risk populations such as persons who inject drugs. In 2015, Georgia embarked on an elimination program for HCV which includes the expansion of HCV testing, linkage to care, and treatment.

The country made a substantial progress in HCV testing, linkage to care and treatment during the last five years, but the gap still remains that needs to be addressed through testing of different screening modalities to reach marginalized groups of the population.

Self-testing with easy-to-use rapid diagnostic tests has been successfully used for diseases such as HIV. The availability of self-testing has been shown to increase testing rates and testing acceptability in diverse populations around the world, in large part due to its convenience and privacy advantages. The present study aims to evaluate the acceptability and impact of an online program enabling home delivery of HCV self-testing (HCVST) for people who inject drugs (PWID) and men who have sex with men (MSM) in Georgia.

The National Centres for Disease Control (NCDC) and FIND, in conjunction with the Georgian national HCV elimination program, Batumi Imedi, Equality Movement, Tanadgoma, and Tbilisi New Way are evaluating HCV self-testing as a way to expand outreach, improve HCV testing rates, and increase linkage to care among HCV-infected PWID and MSM. The ability to utilize an existing online platform promoting HIV self-testing, selftest.ge, will enable the study to examine how offering HCV self-testing may help Georgia reach its goal of nationwide elimination of HCV

The study aims to describe the acceptability and impact of an online platform offering home delivery of HCV self-tests to PWID and MSM. Since HCV self-tests detect the presence of antibodies to HCV, indicating exposure to HCV, any individual reporting a positive HCV self-test will be referred to HCV RNA confirmatory testing in order to identify active HCV infection. Those confirmed to have active HCV infection with a positive HCV RNA test will be linked to HCV treatment and care. Rates of testing and linkage to care will be measured, along with knowledge, attitudes, and practices around HCV testing and care

This is a randomized controlled trial comparing an online platform providing home-delivery of HCV self-tests to referral to standard of care community-based HCV testing sites in PWID and MSM in Georgia.

Study participants will be recruited through an existing HIV self-testing program using an online platform to promote the study. Interested participants will sign up to be contacted for study eligibility screening and consent. All study participants will complete a baseline survey collecting demographics and knowledge and attitudes towards HCV testing.

Randomization will be done among participants who primarily identify as MSM (arm 1, 2 and 3) and separately among participant who primarily identify as PWID

• Arm 1: MSM postal delivery Participants who identify primarily as MSM will receive a home delivered HCV self-test kit in non-identifiable packaging. The kit will include the test, instructions for use (IFU), and information about additional supporting materials, such as access to live chat and a call center for questions about testing
• Arm 2: MSM peer delivery Participants who identify primarily as MSM will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
• Arm 3: MSM control Participants who identify primarily as MSM will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing
• Arm 4: PWID peer delivery Participants who identify primarily as PWID will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
• Arm 5: PWID control Participants who identify primarily as PWID will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing All participants will be sent a telephone reminder Follow-up survey #1 which includes the opportunity to upload any testing result approximately 2-4 weeks after enrolment. A second Follow-up survey will be sent after the closure of the first survey. Up to 3 reminders may be sent for each survey if a survey has not been completed. Participants will receive 10 GEL phone credit (~3 USD) for completion of the first follow up questionnaire to enter test result and an additional 10 GEL for completion of the follow-up survey.

Any participants who report HCV antibody positive result through the study will be contacted by the project staff and offered confirmatory testing and appropriate linkage to care through the national HCV program. For all arms study staff will contact to the participants who report HCV antibody positive result via the online platform and will provide information about the next steps for diagnostic and treatment, information about the treatment facilities. Those participants will be contacted again after 6 weeks and will be asked if they received the next HCV care.

The HCV test used in the intervention group is an oral fluid test (OraQuick® HCV Self-Test). Although use as a self-test is still research use only, it has been validated by the manufacturer for self-testing. The test has also already been CE marked and WHO pre-qualified as an in vitro diagnostic for professional use by healthcare workers.

Conditions

Hepatitis C; Diagnostic Self Evaluation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

MSM Postal delivery

Participants who identify primarily as MSM will receive a home delivered HCV self-test kit in non-identifiable packaging. The kit will include the test, instructions for use (IFU), and information about additional supporting materials, such as access to live chat and a call center for questions about testing

Group Type: EXPERIMENTAL

(OraQuick® HCV Self-Test

Intervention Type: DIAGNOSTIC_TEST

The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.

MSM Peer delivery

Participants who identify primarily as MSM will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing

Group Type: EXPERIMENTAL

(OraQuick® HCV Self-Test

Intervention Type: DIAGNOSTIC_TEST

The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.

MSM control

Participants who identify primarily as MSM will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing

Group Type: NO_INTERVENTION

No interventions assigned to this group

PWID peer delivery

Participants who identify primarily as PWID will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing

Group Type: EXPERIMENTAL

(OraQuick® HCV Self-Test

Intervention Type: DIAGNOSTIC_TEST

The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.

PWID control

Participants who identify primarily as PWID will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

(OraQuick® HCV Self-Test

The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• Able and eligible to access services on selftest.ge
• Self-identify as a PWID and or MSM
• Living in Batumi or Tbilisi
• Able to understand the scope of the study and provide informed consent through online platform.
• Able to read and understand Georgian
• Unknown HCV serology status (i.e., never tested for HCV or tested HCV ab- in a most recent test performed no later than 6 months before enrolment)

Exclusion Criteria

• Self-reported previously confirmed positive HCV status (either Ab or RNA)
• Un-eligible for Georgian National Hepatitis Elimination program

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Center for Disease control and Public Health

OTHER_GOV

Sponsor Role: collaborator

Batumi Imedi Harm Reduction Site

UNKNOWN

Sponsor Role: collaborator

Equality Movement

UNKNOWN

Sponsor Role: collaborator

Center for Information and Counseling on Reproductive Health - Tanadgoma

OTHER

Sponsor Role: collaborator

Tbilisi New Way Harm Reduction Site

UNKNOWN

Sponsor Role: collaborator

Foundation for Innovative New Diagnostics, Switzerland

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ketevan Stvilia

Role: PRINCIPAL_INVESTIGATOR

National Center for Disease Control and Public Health, Georgia

Locations

Center for Information and Counselling on Reproductive Health-Tanadgoma

Batumi, , Georgia

Site Status: RECRUITING

Equality Movement

Batumi, , Georgia

Site Status: RECRUITING

Imedi Harm Reduction Site

Batumi, , Georgia

Site Status: RECRUITING

Center for Information and Counselling on Reproductive Health-Tanadgoma

Tbilisi, , Georgia

Site Status: RECRUITING

Equality Movement

Tbilisi, , Georgia

Site Status: RECRUITING

Tbilisi New Way Harm Reduction Site

Tbilisi, , Georgia

Site Status: RECRUITING

Countries

Georgia

Central Contacts

Sonjelle Shilton

Role: CONTACT

Sonjelle.Shilton@finddx.org

+41 (22) 710 05 90

Facility Contacts

Nino Tsereteli

Role: primary

Shota Pevadze

Role: primary

Miranda Jgenti

Role: primary

Nino Tsereteli

Role: primary

Shota Pevadze

Role: primary

Dali Usharidze

Role: primary

References

Shilton S, Stvilia K, Japaridze M, Tsereteli N, Usharidze D, Phevadze S, Jghenti M, Mozalevskis A, Markby J, Luhmann N, Johnson C, Nabeta P, Ongarello S, Reipold EI, Gamkrelidze A. Home-based hepatitis C self-testing in people who inject drugs and men who have sex with men in Georgia: a protocol for a randomised controlled trial. BMJ Open. 2022 Sep 8;12(9):e056243. doi: 10.1136/bmjopen-2021-056243.

Reference Type: DERIVED

PMID: 36691209 (View on PubMed)

Other Identifiers

HC022

Identifier Type: -

Identifier Source: org_study_id